34 results on '"de Kuiper, R."'
Search Results
2. Recovery of VZV-Specific T- and B-Cell Responses by Herpes Zoster Infection after Lung Transplantation.: Abstract# 622: Poster Board #-Session: P90-I
- Author
-
van Besouw, N. M., van Hal, P. T. W., Zuijderwijk, J. M., de Kuiper, R., Verjans, G. M. G. M., and Weimar, W.
- Published
- 2012
3. Donor-specific Immune Regulation by CD8+ Lymphocytes Expanded from Rejecting Human Cardiac Allografts
- Author
-
Dijke, I. E., Klepper, M., de Kuiper, R., Balk, A. H. M. M., Maat, A. P. W. M., Weimar, W., and Baan, C. C.
- Published
- 2009
- Full Text
- View/download PDF
4. Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes
- Author
-
Went, M., Kinnersley, B., Sud, A., Johnson, D.C. (David), Weinhold, N, Försti, A. (Asta), Duin, M. (Mark) van, Orlando, G., Mitchell, JS, de Kuiper, R., Walker, BA, Gregory, WM, Hoffmann, P. (Per), Jackson, G. (Graham), Nöthen, M.M. (Markus), da Silva, MI, Thomsen, H, Broyl, A. (Annemiek), Davies, F.E., Thorsteinsdottir, U. (Unnur), Hansson, M, Kaiser, M, Sonneveld, P. (Pieter), Goldschmidt, H. (Hartmut), Zwart, J-A. (John-Anker), Hemminki, K. (Kari), Nilsson, B, Morgan, G.J., Houlston, R. (Richard), Went, M., Kinnersley, B., Sud, A., Johnson, D.C. (David), Weinhold, N, Försti, A. (Asta), Duin, M. (Mark) van, Orlando, G., Mitchell, JS, de Kuiper, R., Walker, BA, Gregory, WM, Hoffmann, P. (Per), Jackson, G. (Graham), Nöthen, M.M. (Markus), da Silva, MI, Thomsen, H, Broyl, A. (Annemiek), Davies, F.E., Thorsteinsdottir, U. (Unnur), Hansson, M, Kaiser, M, Sonneveld, P. (Pieter), Goldschmidt, H. (Hartmut), Zwart, J-A. (John-Anker), Hemminki, K. (Kari), Nilsson, B, Morgan, G.J., and Houlston, R. (Richard)
- Abstract
Background: While genome-wide association studies (GWAS) of multiple myeloma (MM) have identified variants at 23 regions influencing risk, the genes underlying these associations are largely unknown. To identify candidate causal genes at these regions and search for novel risk regions, we performed a multi-tissue transcriptome-wide association study (TWAS). Results: GWAS data on 7319 MM cases and 234,385 controls was integrated with Genotype-Tissue Expression Project (GTEx) data assayed in 48 tissues (sample sizes, N = 80–491), including lymphocyte cell lines and whole blood, to predict gene expression. We identified 108 genes at 13 independent regions associated with MM risk, all of which were in 1 Mb of known MM GWAS risk variants. Of these, 94 genes, located in eight regions, had not previously been considered as a candidate gene for that locus. Conclusions: Our findings highlight the value of leveraging expression data from multiple tissues to identify candidate genes responsible for GWAS associations which provide insight into MM tumorigenesis. Among the genes identified, a number have plausible roles in MM biology, notably APOBEC3C, APOBEC3H, APOBEC3D, APOBEC3F, APOBEC3G, or have been previously implicated in other malignancies. The genes identified in this TWAS can be explored for follow-up and validation to further understand their role in MM biology.
- Published
- 2019
- Full Text
- View/download PDF
5. The Number of Donor-Specific IL-21 Producing Cells Before and After Transplantation Predicts Kidney Graft Rejection
- Author
-
Besouw, N.M. (Nicole) van, Yan, L. (Lei), de Kuiper, R., Klepper, M. (Mariska), Reijerkerk, D., Dieterich, M. (Marjolein), Roelen, D.L., Claas, F.H.J. (Frans), van Groningen, M., Hesselink, D.A. (Dennis), Baan, C.C. (Carla), Besouw, N.M. (Nicole) van, Yan, L. (Lei), de Kuiper, R., Klepper, M. (Mariska), Reijerkerk, D., Dieterich, M. (Marjolein), Roelen, D.L., Claas, F.H.J. (Frans), van Groningen, M., Hesselink, D.A. (Dennis), and Baan, C.C. (Carla)
- Published
- 2019
- Full Text
- View/download PDF
6. Boosting the Adaptive Immune Response Prevents the High Incidence of Herpes Zoster After Lung or Heart Transplantation
- Author
-
van Besouw, N.M., primary, Roest, S., additional, Zuijderwijk, J.M., additional, de Kuiper, R., additional, van Weezel, J.J., additional, Hoek, R.A., additional, van der Eijk, A.A., additional, Weimar, W., additional, van Hal, P.T., additional, and Manintveld, O.C., additional
- Published
- 2015
- Full Text
- View/download PDF
7. High Incidence of Herpes Zoster After Lung Transplantation.
- Author
-
van Besouw, N., primary, van Weezel, J., additional, Zuijderwijk, J., additional, de Kuiper, R., additional, van der Eijk, A., additional, Weimar, W., additional, and van Hal, P., additional
- Published
- 2014
- Full Text
- View/download PDF
8. Donor-specific Immune Regulation by CD8+ Lymphocytes Expanded from Rejecting Human Cardiac Allografts
- Author
-
Dijkea, I.E., Caliskan, K., Klepper, M., de Kuiper, R., Balk, A.H.M.M., Maat, A.P.W.M., Weimar, W., and Baan, C.C.
- Published
- 2009
- Full Text
- View/download PDF
9. 691 Recovery of VZV-Specific T- and B-Cell Responses by Herpes Zoster Infection after Lung Transplantation
- Author
-
van Besouw, N.M., primary, van Hal, P. Th.W., additional, Zuijderwijk, J.M., additional, de Kuiper, R., additional, Verjans, G.M.G.M., additional, and Weimar, W., additional
- Published
- 2012
- Full Text
- View/download PDF
10. 355 Induction of VZV-Specific Effector Memory T-Cell Response by Herpes Zoster Infection after Lung Transplantation
- Author
-
van Besouw, N.M., primary, van Hal, P.T., additional, Verjans, G.M., additional, Zuijderwijk, J.M., additional, de Kuiper, R., additional, and Weimar, W., additional
- Published
- 2011
- Full Text
- View/download PDF
11. (319) - Boosting the Adaptive Immune Response Prevents the High Incidence of Herpes Zoster After Lung or Heart Transplantation
- Author
-
van Besouw, N.M., Roest, S., Zuijderwijk, J.M., de Kuiper, R., van Weezel, J.J., Hoek, R.A., van der Eijk, A.A., Weimar, W., van Hal, P.T., and Manintveld, O.C.
- Published
- 2015
- Full Text
- View/download PDF
12. IMMUNOGENICITY OF HUMAN MESENCHYMAL STEM CELLS; SUSCEPTIBILITY FOR CD8+ T CELL AND NK CELL MEDIATED LYSIS
- Author
-
Hoogduijn, M. J., primary, Crop, M. J., additional, Korevaar, S. S., additional, de Kuiper, R., additional, van Besouw, N. M., additional, IJzermans, J. N., additional, Baan, C., additional, and Weimar, W., additional
- Published
- 2010
- Full Text
- View/download PDF
13. FoxP3+ T Cells Can Be Expanded From Rejecting Cardiac Allografts
- Author
-
Dijke, E., primary, Velthuis, J., additional, Balk, A., additional, de Kuiper, R., additional, Klepper, M., additional, Caliskan, K., additional, Weimar, W., additional, and Baan, C., additional
- Published
- 2006
- Full Text
- View/download PDF
14. Distribution of T cells and signs of T-cell activation in the rheumatoid joint: implications for semiquantitative comparative histology
- Author
-
Dolhain, R. J., primary, Ter Haar, N. T., additional, De Kuiper, R., additional, Nieuwenhuis, I. G., additional, Zwinderman, A. H., additional, Breedveld, F. C., additional, and Miltenburg, A. M., additional
- Published
- 1998
- Full Text
- View/download PDF
15. Distribution of T cells and signs of T-cell activation in the rheumatoid joint: implications for semiquantitative comparative histology.
- Author
-
Dolhain, RJEM, Ter Haar, NT, de Kuiper, R, Nieuwenhuis, IG, Zwinderman, AH, and Breedveld, FC
- Abstract
A prerequisite for comparative histology of synovial tissue by means of biopsies is insight into the distribution of a marker under study. This investigation focuses on the variation in the presence of T cells and signs of T-cell activation within the rheumatoid joint. For this purpose, multiple slides from several pieces of synovial tissue from different parts of a joint were stained and scored for the expression of CD3, CD25, HLA-DR, Ki67 and interferon-γ. The variation in scores for the presence of T cells and markers of activation was more pronounced in slides prepared from different pieces of tissue than in slides from one piece of tissue. Based on multiple analysis of variance, methods are suggested to establish a reliable overall score for the expression of a certain marker within a joint. Following validation, such methods may prove to be useful by allowing semiquantitative histology of synovial tissue for studies on arthritis. [ABSTRACT FROM PUBLISHER]
- Published
- 1998
- Full Text
- View/download PDF
16. T Cells Cloned from Human Rheumatoid Synovial Membrane Functionally Represent the Th1 Subset.
- Author
-
Miltenburg, A. M. M., van Laar, J. M., de Kuiper, R., Daha, M. R., and Breedveld, F. C.
- Subjects
T cells ,RHEUMATOID arthritis ,ARTHRITIS ,CELLS ,CYTOKINES ,AUTOIMMUNE diseases ,CELLULAR immunity - Abstract
The presence of activated T cells in the synovial membrane of patients with rheumatoid arthritis (RA) suggests a role for these cells in the pathogenesis of the disease. Recent evidence indicates that human T cells may fall into functional categories dependent on their cytokine profile and cytotoxic capacity. The human Th1 subset is cytolytic and produces high levels of IFN-gamma whereas the Th2 type of T cell produces IL-4. In order to investigate whether Th1 or Th2 type cells are present in the inflammatory synovial membrane in RA, a panel of synovial membrane derived T-cell clones (n = 19) was generated and studied functionally. Anti-CD3-induced cytotoxicity assays were performed to demonstrate the cytotoxic potential of clones. Except for two, all clones were cytolytic in this test. Clone cells were activated to initiate cytokine production and assessment of the cytokine levels showed that all clones produced large amounts of IFN-gamma (18 out of 19 clones: over 50,000 pg/ml) whereas IL-4 was absent or present in minimal amounts (17 out of 19 clones: less than 1000 pg/ml). The production of IL-1. IL-2 and IL-6 was variable. The functional characteristics of the clones studied indicate that they may resemble the Th1 subtype of T cells. Our data suggest a relation between Th1-type functions and the chronic inflammation characteristic of RA. [ABSTRACT FROM AUTHOR]
- Published
- 1992
- Full Text
- View/download PDF
17. Donor-specific Immune Regulation by CD8+ Lymphocytes Expanded from Rejecting Human Cardiac Allografts
- Author
-
Dijke, I. E., Caliskan, K., Klepper, M., de Kuiper, R., Balk, A. H. M. M., Maat, A. P. W. M., Weimar, W., and Baan, C. C.
- Abstract
To assess whether regulatory T cells are present in rejecting human cardiac allografts, we performed functional analyses of graft lymphocytes (GLs) expanded from endomyocardial biopsies (EMB; n 5) with histological signs of acute cellular rejection. The GL cultures were tested for their proliferative capacity and regulatory activity on allogeneic-stimulated peripheral blood mononuclear cells (PBMC) of the patient (ratio PBMC:GLs 5:1). Three of these GL cultures were hyporesponsive to donor antigens and suppressed the antidonor proliferative T-cell response of PBMC, but not the anti-third-party response. Interestingly, it was the CD8GL subset of these cultures that inhibited the antidonor response (65-91 inhibition of the proportion of proliferating cells); the CD4GLs of the expanded GL cultures were not suppressive. In conclusion, CD8GLs expanded from rejecting human cardiac allografts can exhibit donor-specific immune regulatory activities in vitro. We suggest that during acute cellular rejection, GLs may not only consist of graft-destructing effector T cells, but also of cells of the CD8type with the potential to specifically inhibit antidonor immune reactivity.
- Published
- 2009
- Full Text
- View/download PDF
18. Donor-specific Immune Regulation by CD8+Lymphocytes Expanded from Rejecting Human Cardiac Allografts
- Author
-
Dijkea, I.E., Caliskan, K., Klepper, M., de Kuiper, R., Balk, A.H.M.M., Maat, A.P.W.M., Weimar, W., and Baan, C.C.
- Abstract
To assess whether regulatory T cells are present in rejecting human cardiac allografts, we performed functional analyses of graft lymphocytes (GLs) expanded from endomyocardial biopsies (EMB; n = 5) with histological signs of acute cellular rejection. The GL cultures were tested for their proliferative capacity and regulatory activity on allogeneic-stimulated peripheral blood mononuclear cells (PBMC) of the patient (ratio PBMC:GLs = 5:1). Three of these GL cultures were hyporesponsive to donor antigens and suppressed the antidonor proliferative T-cell response of PBMC, but not the anti-third-party response. Interestingly, it was the CD8+GL subset of these cultures that inhibited the antidonor response (65–91% inhibition of the proportion of proliferating cells); the CD4+GLs of the expanded GL cultures were not suppressive. In conclusion, CD8+GLs expanded from rejecting human cardiac allografts can exhibit donor-specific immune regulatory activities in vitro. We suggest that during acute cellular rejection, GLs may not only consist of graft-destructing effector T cells, but also of cells of the CD8+type with the potential to specifically inhibit antidonor immune reactivity.
- Published
- 2009
- Full Text
- View/download PDF
19. Repeated COVID-19 Vaccination Drives Memory T- and B-cell Responses in Kidney Transplant Recipients: Results From a Multicenter Randomized Controlled Trial.
- Author
-
Malahe SRK, den Hartog Y, Rietdijk WJR, van Baarle D, de Kuiper R, Reijerkerk D, Ras AM, Geers D, Diavatopoulos DA, Messchendorp AL, van der Molen RG, Imhof C, Frölke SC, Bemelman FJ, Gansevoort RT, Hilbrands LB, Sanders JF, GeurtsvanKessel CH, Kho MML, de Vries RD, Reinders MEJ, and Baan CC
- Abstract
Background: Insight into cellular immune responses to COVID-19 vaccinations is crucial for optimizing booster programs in kidney transplant recipients (KTRs)., Methods: In an immunologic substudy of a multicenter randomized controlled trial (NCT05030974) investigating different repeated vaccination strategies in KTR who showed poor serological responses after 2 or 3 doses of an messenger RNA (mRNA)-based vaccine, we compared SARS-CoV-2-specific interleukin-21 memory T-cell and B-cell responses by enzyme-linked immunosorbent spot (ELISpot) assays and serum IgG antibody levels. Patients were randomized to receive: a single dose of mRNA-1273 (100 μg, n = 25), a double dose of mRNA-1273 (2 × 100 μg, n = 25), or a single dose of adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2.S) (n = 25). In parallel, we also examined responses in 50 KTR receiving 100 μg mRNA-1273, randomized to continue (n = 25) or discontinue (n = 25) mycophenolate mofetil/mycophenolic acid. As a reference, the data were compared with KTR who received 2 primary mRNA-1273 vaccinations., Results: Repeated vaccination increased the seroconversion rate from 21% to 66% in all patients, which was strongly associated with enhanced levels of SARS-CoV-2-specific interleukin-21 memory T cells (odd ratio, 3.84 [1.89-7.78]; P < 0.001) and B cells (odd ratio, 35.93 [6.94-186.04]; P < 0.001). There were no significant differences observed in these responses among various vaccination strategies. In contrast to KTR vaccinated with 2 primary vaccinations, the number of antigen-specific memory B cells demonstrated potential for classifying seroconversion after repeated vaccination (area under the curve, 0.64; 95% confidence interval, 0.37-0.90; P = 0.26 and area under the curve, 0.95; confidence interval, 0.87-0.97; P < 0.0001, respectively)., Conclusions: Our study emphasizes the importance of virus-specific memory T- and B-cell responses for comprehensive understanding of COVID-19 vaccine efficacy among KTR., Competing Interests: The authors declare no conflicts of interest., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
20. The role of interleukin-21 in COVID-19 vaccine-induced B cell-mediated immune responses in patients with kidney disease and kidney transplant recipients.
- Author
-
Malahe SRK, Hartog YD, Rietdijk WJR, van Baarle D, de Kuiper R, Reijerkerk D, Ras AM, Geers D, Diavatopoulos DA, Messchendorp AL, van der Molen RG, Remmerswaal EBM, Bemelman FJ, Gansevoort RT, Hilbrands LB, Sanders JS, GeurtsvanKessel CH, Kho MML, de Vries RD, Reinders MEJ, and Baan CC
- Subjects
- Humans, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, SARS-CoV-2, Interleukins, Immunoglobulin G, Antibodies, Viral, Immunity, Transplant Recipients, Kidney Transplantation, COVID-19, Kidney Diseases
- Abstract
T-cell-mediated help to B cells is required for the development of humoral responses, in which the cytokine interleukin (IL)-21 is key. Here, we studied the mRNA-1273 vaccine-induced SARS-CoV-2-specific memory T-cell IL-21 response, memory B cell response, and immunoglobulin (Ig)G antibody levels in peripheral blood at 28 days after the second vaccination by ELISpot and the fluorescent bead-based multiplex immunoassay, respectively. We included 40 patients with chronic kidney disease (CKD), 34 patients on dialysis, 63 kidney transplant recipients (KTR), and 47 controls. We found that KTR, but not patients with CKD and those receiving dialysis, showed a significantly lower number of SARS-CoV-2-specific IL-21 producing T cells than controls (P < .001). KTR and patients with CKD showed lower numbers of SARS-CoV-2-specific IgG-producing memory B cells when compared with controls (P < .001 and P = .01, respectively). The T-cell IL-21 response was positively associated with the SARS-CoV-2-specific B cell response and the SARS-CoV-2 spike S1-specific IgG antibody levels (both Pearson r = 0.5; P < .001). In addition, SARS-CoV-2-specific B cell responses were shown to be IL-21 dependent. Taken together, we show that IL-21 signaling is important in eliciting robust B cell-mediated immune responses in patients with kidney disease and KTR., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
21. Alloreactive T cells to Assess Acute Rejection Risk in Kidney Transplant Recipients.
- Author
-
Mendoza Rojas A, Verhoeven JGHP, de Kuiper R, Clahsen-van Groningen MC, Boer K, Hesselink DA, van Gelder T, van Besouw NM, and Baan CC
- Abstract
Memory T cells are important mediators of transplant rejection but are not routinely measured before or after kidney transplantation. The aims of this study were as follows: (1) validate whether pretransplant donor-reactive memory T cells are reliable predictors of acute rejection (AR) (2) determine whether donor-reactive memory T cells can distinguish AR from other causes of transplant dysfunction., Methods: Samples from 103 consecutive kidney transplant recipients (2018-2019) were obtained pretransplantation and at time of for-cause biopsy sampling within 6 mo of transplantation. The number of donor-reactive interferon gamma (IFN-γ) and interleukin (IL)-21-producing memory T cells was analyzed by enzyme-linked immunosorbent spot (ELISPOT) assay., Results: Of the 63 patients who underwent a biopsy, 25 had a biopsy-proven acute rejection (BPAR; 22 aTCMR and 3 aAMR), 19 had a presumed rejection, and 19 had no rejection. Receiver operating characteristic analysis showed that the pretransplant IFN-γ ELISPOT assay distinguished between patients who later developed BPAR and patients who remained rejection-free (area under the curve [AUC] 0.73; sensitivity 96% and specificity 41%). Both the IFN-γ and IL-21 assays were able to discriminate BPAR from other causes of transplant dysfunction (AUC 0.81; sensitivity 87% and specificity 76% and AUC 0.81; sensitivity 93% and specificity 68%, respectively)., Conclusions: This study validates that a high number of donor-reactive memory T cells before transplantation is associated with the development of AR after transplantation. Furthermore, it demonstrates that the IFN-γ and IL-21 ELISPOT assays are able to discriminate between patients with AR and patients without AR at the time of biopsy sampling., Competing Interests: D.A.H. has received lecture and consulting fees from Astellas Pharma and Chiesi Farmaceutici SpA, as well as grant support from Astellas Pharma, Chiesi Farmaceutici SpA, and Bristol Myers-Squibb. M.C.C.v.G. received project funding from Astellas Pharma paid to the Erasmus MC and is a consultant for Sangamo Therapeutics, Inc. T.v.G. reports study grants from Astellas Pharma and Chiesi Farmaceutici SpA and honoraria for lectures or consulting from Astellas Pharma and Novartis. The other authors declare no conflicts of interest., (Copyright © 2023 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
22. Boosting the VZV-Specific Memory B and T Cell Response to Prevent Herpes Zoster After Kidney Transplantation.
- Author
-
Kho MML, Weimar W, Malahe SRK, Zuijderwijk JM, de Kuiper R, Boer-Verschragen MJ, van der Eijk AA, Hesselink DA, Reinders MEJ, and van Besouw NM
- Subjects
- Antibodies, Viral, Herpesvirus 3, Human, Humans, Immunity, Cellular, Immunoglobulin G, Vaccines, Attenuated, Herpes Zoster prevention & control, Kidney Failure, Chronic, Kidney Transplantation adverse effects
- Abstract
Background: Solid organ transplant recipients are at high risk to develop (complicated) herpes zoster (HZ). Booster vaccination could prevent HZ. However, end-stage renal disease (ESRD) patients show poor immunological responses to vaccinations. We studied the effect of a live attenuated VZV booster vaccine on VZV-specific B and T cell memory responses in ESRD patients and healthy controls. NL28557.000.09, www.toetsingonline.nl., Methods: VZV-seropositive patients, aged ≥50 years, awaiting kidney transplantation, were vaccinated with Zostavax
® . Gender and age-matched VZV-seropositive potential living kidney donors were included as controls. VZV-specific IgG titers were measured before, at 1, 3 and 12 months post-vaccination. VZV-specific B and T cell responses before, at 3 months and 1 year after vaccination were analysed by flow-cytometry and Elispot, respectively. Occurrence of HZ was assessed at 5 years post-vaccination., Results: 26 patients and 27 donors were included. Median VZV-specific IgG titers were significantly higher at all time-points post-vaccination in patients (mo 1: 3104 IU/ml [1967-3825], p<0.0001; mo 3: 2659 [1615-3156], p=0.0002; mo 12: 1988 [1104-2989], p=0.01 vs. pre: 1397 [613-2248]) and in donors (mo 1: 2981 [2126-3827], p<0.0001; mo 3: 2442 [2014-3311], p<0.0001; mo 12: 1788 [1368-2460], p=0.0005 vs. pre: 1034 [901-1744]. The patients' IgG titers were comparable to the donors' at all time-points. The ratio VZV-specific B cells of total IgG producing memory B cells had increased 3 months post-vaccination in patients (0.85 [0.65-1.34] vs. pre: 0.56 [0.35-0.81], p=0.003) and donors (0.85 [0.63-1.06] vs. pre: 0.53 [0.36-0.79], p<0.0001) and remained stable thereafter in donors. One year post-vaccination, the percentage of CD4+ central memory cells had increased in both patients (0.29 [0.08-0.38] vs. 0.12 [0.05-0.29], p=0.005) and donors (0.12 [0.03-0.37] vs. 0.09 [0.01-0.20], p=0.002) and CD4+ effector memory cells had increased in donors (0.07 [0.02-0.14] vs. 0.04 [0.01-0.12], p=0.007). Only 1 patient experienced HZ, which was non-complicated., Conclusion: VZV booster vaccination increases VZV-specific IgG titers and percentage VZV-specific memory T-cells for at least 1 year both in ESRD patients and healthy controls. VZV-specific memory B cells significantly increased in patients up to 3 months after vaccination. Prophylactic VZV booster vaccination prior to transplantation could reduce HZ incidence and severity after transplantation., Competing Interests: Author MK received a honorarium for participation in a scientific advisory board from Takeda. Author DH has received lecture fees and consulting fees from Astellas Pharma, Chiesi Pharma, Medincell, Novartis Pharma, Sangamo Therapeutics and Vifor Pharma. He has received grant support from Astellas Pharma, Bristol-Myers Squibb and Chiesi Pharma [paid to his institution]. Author DA Hesselink does not have employment or stock ownership at any of these companies, and neither does he have patents or patent applications. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Kho, Weimar, Malahe, Zuijderwijk, de Kuiper, Boer-Verschragen, Eijk, Hesselink, Reinders and van Besouw.)- Published
- 2022
- Full Text
- View/download PDF
23. High Tacrolimus Intrapatient Variability and Subtherapeutic Immunosuppression are Associated With Adverse Kidney Transplant Outcomes.
- Author
-
Mendoza Rojas A, Hesselink DA, van Besouw NM, Dieterich M, de Kuiper R, Baan CC, and van Gelder T
- Subjects
- Graft Rejection prevention & control, Graft Survival, Humans, Immunosuppression Therapy, Immunosuppressive Agents adverse effects, Mycophenolic Acid therapeutic use, Retrospective Studies, Kidney Transplantation, Tacrolimus therapeutic use
- Abstract
Background: Kidney transplant recipients with high intrapatient variability (IPV) in tacrolimus (Tac) exposure experience more rejection and reduced graft survival. To understand the underlying pathophysiology of this association, the authors investigated whether patients with high tacrolimus IPV have a more activated immune system than patients with low IPV. In addition, exposure to tacrolimus and mycophenolic acid (MPA) was studied in relation to rejection and graft survival., Methods: At the time of patient inclusion (5-7 years post-transplantation), the frequency of donor-reactive cells was determined by enzyme-linked immunosorbent assay, and the development of donor-specific anti-Human Leukocyte Antigen antibodies (DSA) was measured by Luminex Single Antigen assay. Tacrolimus IPV was retrospectively calculated between 6 and 12 months and the exposure to tacrolimus and MPA was determined between 1 and 5 years post-transplantation., Results: A total of 371 kidney transplant recipients were included in this study, of whom 56 developed a rejection episode after 12 months and 60 experienced graft failure after 5-7 years. No correlations were found between tacrolimus IPV or immunosuppression exposure and the number of donor-reactive cells after 5 years of transplantation. DSA were detected more often in patients with low exposure to both tacrolimus and MMF [4/21 (19%) versus 17/350 (4.9%), P = 0.04]. In this cohort, neither tacrolimus IPV nor low overall immunosuppression exposure was associated with a higher incidence of rejection. However, regression analysis showed that a higher tacrolimus IPV was associated with an increased incidence of graft failure (odds ratio = 1.03, P = 0.02)., Conclusions: This study verifies the relationship between high tacrolimus IPV and impaired kidney allograft survival in long-term follow-up. DSA was also found to be more prevalent in patients with subtherapeutic concentrations of tacrolimus and MPA. An increased prevalence of donor-specific alloreactivity is yet to be demonstrated in patients with high IPV., Competing Interests: D. A. Hesselink has received lecture and consulting fees from Astellas Pharma and Chiesi Farmaceutici SpA, including grant support from Astellas Pharma, Chiesi Farmaceutici SpA, and Bristol Myers-Squibb. T. van Gelder reports study grants from Astellas Pharma and Chiesi Farmaceutici SpA, including honoraria for lectures or consultations from Astellas Pharma and Novartis. The other authors declare no conflict of interest., (Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.)
- Published
- 2022
- Full Text
- View/download PDF
24. Natural Antibodies and Alloreactive T Cells Long after Kidney Transplantation.
- Author
-
van Besouw NM, Rojas AM, See SB, de Kuiper R, Dieterich M, Roelen DL, Clahsen-van Groningen MC, Hesselink DA, Zorn E, and Baan CC
- Abstract
Background: The relationship between circulating effector memory T and B cells long after transplantation and their susceptibility to immunosuppression are unknown. To investigate the impact of antirejection therapy on T cell-B cell coordinated immune responses, we assessed IFN- γ -producing memory cells and natural antibodies (nAbs) that potentially bind to autoantigens on the graft., Methods: Plasma levels of IgG nAbs to malondialdehyde (MDA) were measured in 145 kidney transplant recipients at 5-7 years after transplantation. In 54 of these patients, the number of donor-reactive IFN- γ -producing cells was determined. 35/145 patients experienced rejection, 18 of which occurred within 1 year after transplantation., Results: The number of donor-reactive IFN- γ -producing cells and the levels of nAbs were comparable between rejectors and nonrejectors. The nAbs levels were positively correlated with the number of donor-reactive IFN- γ -producing cells ( r
s = 0.39, p =0.004). The positive correlation was only observed in rejectors ( rs = 0.53, p =0.003; nonrejectors: rs = 0.24, p =0.23). Moreover, we observed that intravenous immune globulin treatment affected the level of nAbs and this effect was found in patients who experienced a late ca-ABMR compared to nonrejectors ( p =0.008)., Conclusion: The positive correlation found between alloreactive T cells and nAbs in rejectors suggests an intricate role for both components of the immune response in the rejection process. Treatment with intravenous immune globulin impacted nAbs., Competing Interests: The authors declare no conflicts of interest., (Copyright © 2021 Nicole M. van Besouw et al.)- Published
- 2021
- Full Text
- View/download PDF
25. Pre-transplant donor-reactive IL-21 producing T cells as a tool to identify an increased risk for acute rejection.
- Author
-
Mendoza Rojas A, van Gelder T, de Kuiper R, Reijerkerk D, Clahsen-van Groningen MC, Hesselink DA, Baan CC, and van Besouw NM
- Subjects
- Adult, Age Factors, Aged, Cross-Sectional Studies, Enzyme-Linked Immunospot Assay, Female, Graft Rejection immunology, Graft Survival immunology, HLA Antigens immunology, Humans, Interferon-gamma metabolism, Interleukins, Isoantibodies immunology, Lymphocyte Count, Male, Middle Aged, Preoperative Period, Risk Assessment methods, Risk Factors, T-Lymphocytes metabolism, Young Adult, Graft Rejection epidemiology, Histocompatibility Testing methods, Isoantibodies blood, Kidney Transplantation adverse effects, T-Lymphocytes immunology
- Abstract
Pre-transplant screening focuses on the detection of anti-HLA alloantibodies. Previous studies have shown that IFN-γ and IL-21 producing T cells are associated with the development of acute rejection (AR). The aim of this study, was to assess whether pre-transplant donor-reactive T cells and/or B cells are associated with increased rejection risk. Samples from 114 kidney transplant recipients (transplanted between 2010 and 2013) were obtained pre-transplantation. The number of donor-reactive IFN-γ and IL-21 producing cells was analyzed by ELISPOT assay. The presence of donor specific antibodies (DSA) was also determined before transplantation. Numbers of donor-reactive IFN-γ producing cells were similar in patients with or without AR whereas those of IL-21 producing cells were higher in patients with AR (p = 0.03). Significantly more patients with AR [6/30(20%)] had detectable DSA compared to patients without AR [5/84(5.9%), p = 0.03]. Multivariate logistic regression showed that donor age (OR 1.06), pre-transplant DSA (OR 5.61) and positive IL-21 ELISPOT assay (OR 2.77) were independent predictors of an increased risk for the development of AR. Aside from an advanced donor-age and pre-transplant DSA, also pre-transplant donor-reactive IL-21 producing cells are associated with the development of AR after transplantation.
- Published
- 2021
- Full Text
- View/download PDF
26. The Number of Donor-Specific IL-21 Producing Cells Before and After Transplantation Predicts Kidney Graft Rejection.
- Author
-
van Besouw NM, Yan L, de Kuiper R, Klepper M, Reijerkerk D, Dieterich M, Roelen DL, Claas FHJ, Clahsen-van Groningen MC, Hesselink DA, and Baan CC
- Subjects
- Adult, Aged, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Enzyme-Linked Immunospot Assay methods, Female, Humans, Kidney Diseases immunology, Kidney Transplantation methods, Leukocytes, Mononuclear immunology, Male, Middle Aged, Tissue Donors, Young Adult, Graft Rejection immunology, Interleukins immunology
- Abstract
Interleukin (IL)-21 supports induction and expansion of CD8
+ T cells, and can also regulate the differentiation of B cells into antibody-producing plasma cells. We questioned whether the number of circulating donor-specific IL-21 producing cells (pc) can predict kidney transplant rejection, and evaluated this in two different patient cohorts. The first analysis was done on pre-transplantation samples of 35 kidney transplant recipients of whom 15 patients developed an early acute rejection. The second study concerned peripheral blood mononuclear cell (PBMC) samples from 46 patients obtained at 6 months after kidney transplantation of whom 13 developed late rejection. Significantly higher frequencies of donor-specific IL-21 pc were found by Elispot assay in both patients who developed early and late rejection compared to those without rejection. In addition, low frequencies of donor-specific IL-21 pc were associated with higher rejection-free survival. Moreover, low pre-transplant donor-specific IL-21 pc numbers were associated with the absence of anti-HLA antibodies. Donor-reactive IL-21 was mainly produced by CD4+ T cells, including CD4+ follicular T helper cells. In conclusion, the number of donor-specific IL-21 pc is associated with an increased risk of both early and late rejection, giving it the potential to be a new biomarker in kidney transplantation.- Published
- 2019
- Full Text
- View/download PDF
27. Humoral and cellular response after varicella vaccination in VZV IgG seronegative kidney transplant candidates.
- Author
-
Kho MM, Zuijderwijk JM, van der Eijk AA, de Kuiper R, Boer-Verschragen MJ, Weimar W, and van Besouw NM
- Subjects
- Adult, Aged, Antibodies, Viral blood, Female, Humans, Immunoglobulin G blood, Immunologic Memory, Male, Middle Aged, Prospective Studies, T-Lymphocytes immunology, Vaccines, Attenuated administration & dosage, Vaccines, Attenuated immunology, Young Adult, Chickenpox Vaccine administration & dosage, Chickenpox Vaccine immunology, Herpesvirus 3, Human immunology, Immunity, Cellular, Immunity, Humoral, Kidney Transplantation, Transplant Recipients
- Abstract
Background: In immunocompromised patients, primary infection with VZV may have a disastrous clinical course. Vaccination of VZV-seronegative patients on the waiting list for renal transplantation may prevent severe disease. However, the immunologic response of end-stage renal disease patients to peptide vaccines is far from optimal. Our question was whether end-stage renal disease patients with undetectable VZV-IgG levels were able to mount an adequate humoral and cellular response to a live attenuated varicella vaccine., Methods: Kidney transplant candidates with undetectable VZV levels were vaccinated twice with a live attenuated varicella vaccine at an interval of 6weeks. VZV IgG levels were analysed till 2years after vaccination. The VZV-specific T-cell reactivity was determined prior to vaccination and after transplantation., Results: Seventy-seven percent (40/52) of the vaccinees reached positive VZV-IgG levels after vaccination (responders). Eighty-two percent (9/11) showed an increase in VZV-specific CD4
+ memory T-cells (both central and effector memory cells). The percentage VZV-specific CD8+ memory T-cells did not increase. None of the non-responders suffered from primary VZV after transplantation. No severe vaccine-related adverse events were reported, only spontaneously resolving local skin irritation., Conclusion: The live attenuated varicella vaccine evokes positive VZV IgG-levels and VZV-specific memory T-cells in VZV-seronegative potential kidney transplant candidates., (Copyright © 2016 Elsevier Ltd. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
28. Adipose Tissue-Derived Mesenchymal Stem Cells Have a Heterogenic Cytokine Secretion Profile.
- Author
-
Wu Y, Hoogduijn MJ, Baan CC, Korevaar SS, de Kuiper R, Yan L, Wang L, and van Besouw NM
- Abstract
Mesenchymal stem cells derived from adipose tissue (ASC) have immune regulatory function, which makes them interesting candidates for cellular therapy. ASC cultures are however heterogeneous in phenotype. It is unclear whether all ASC contribute equally to immunomodulatory processes. ASC are also responsive to cytokine stimulation, which may affect the ratio between more and less potent ASC populations. In the present study, we determined IL-6 receptor (CD126 and CD130 subunits) and IFN- γ receptor (CD119) expression on ASC by flow cytometry. The production of IL-6 and IFN- γ was measured by ELISA and the frequency of IL-6 and IFN- γ secreting cells by ELISPOT. The results showed that ASC did not express CD126, and only 10-20% of ASC expressed CD130 on their surface, whereas 18-31% of ASC expressed CD119. ASC produced high levels of IL-6 and 100% of ASC were capable of secreting IL-6. Stimulation by IFN- γ or TGF- β had no effect on IL-6 secretion by ASC. IFN- γ was produced by only 1.4% of ASC, and TGF- β significantly increased the frequency to 2.7%. These results demonstrate that ASC cultures are heterogeneous in their cytokine secretion and receptor expression profiles. This knowledge can be employed for selection of potent, cytokine-producing, or responsive ASC subsets for cellular immunotherapy.
- Published
- 2017
- Full Text
- View/download PDF
29. Herpes zoster after lung transplantation boosts varicella zoster virus-specific adaptive immune responses.
- Author
-
van Besouw NM, van Hal PT, Zuijderwijk JM, de Kuiper R, Hoek RA, van Weezel JJ, van der Eijk AA, Verjans GM, and Weimar W
- Subjects
- Adaptive Immunity, Enzyme-Linked Immunospot Assay, Herpesvirus 3, Human, Humans, Lung Transplantation, Herpes Zoster
- Abstract
Background: Varicella zoster virus (VZV)-specific memory T cells are significantly lower in transplant recipients than in controls. In addition, VZV-specific immunoglobulin G titers are significantly lower after than before transplantation. Data on the incidence and timing of herpes zoster (HZ) after lung transplantation are limited. This study had two aims: first, we investigated the incidence and severity of HZ after lung transplantation; second, we determined the systemic VZV-specific T-cell and B-cell memory responses before and after HZ., Methods: The records of 119 patients who underwent transplantation were analyzed for post-transplant HZ. The VZV-specific B-cell and T-cell memory responses of 5 patients before and after HZ were compared with 5 patients without HZ by enzyme-linked immunospot assay and flow cytometry, respectively., Results: HZ was clinically diagnosed and confirmed by polymerase chain reaction on blister fluids and/or plasma in 17 transplant recipients. Uncomplicated cutaneous HZ was present in 12 patients, and 5 patients had disseminated HZ, of whom 1 died. The incidence of HZ after transplantation (38.2 cases/1,000 patient-years) was significantly higher than the age-matched healthy population (7-8 cases/1,000 patient-years). The frequency of VZV-specific immunoglobulin G-producing B cells (p = 0.06) and the percentage of VZV-specific CD4 and CD8 memory T cells increased after HZ to higher frequencies than in patients without HZ (p = 0.03). This was mainly attributed to VZV-reactive effector memory CD4 T cells (p = 0.02) and central memory (p = 0.02) and effector memory (p = 0.03) CD8 T cells., Conclusions: Lung transplant recipients are highly prone to develop HZ with severe complications. Despite deep immunosuppression, HZ boosted their systemic VZV-specific B-cell and T-cell memory responses., (Copyright © 2016 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
30. Human mesenchymal stem cells are susceptible to lysis by CD8(+) T cells and NK cells.
- Author
-
Crop MJ, Korevaar SS, de Kuiper R, IJzermans JN, van Besouw NM, Baan CC, Weimar W, and Hoogduijn MJ
- Subjects
- Cells, Cultured, Cytotoxicity, Immunologic physiology, Flow Cytometry, Humans, Leukocytes, Mononuclear physiology, CD8-Positive T-Lymphocytes physiology, Killer Cells, Natural physiology, Mesenchymal Stem Cells cytology
- Abstract
There is growing interest in the use of mesenchymal stem cells (MSCs) to improve the outcome of organ transplantation. The immunogenicity of MSCs is, however, unclear and is important for the efficacy of MSC therapy and for potential sensitization against donor antigens. We investigated the susceptibility of autologous and allogeneic MSCs for lysis by CD8(+) T-lymphocytes and NK cells in a kidney transplant setting. MSCs were derived from adipose tissue of human kidney donors and were CD90(+), CD105(+), CD166(+), and HLA class I(+). They showed differentiation ability and immunosuppressive capacity. Lysis of MSCs by peripheral blood mononuclear cells (PBMCs), FACS-sorted CD8(+) T cells, and NK cells was measured by europium release assay. Allogeneic MSCs were susceptible for lysis by cytotoxic CD8(+) T cells and NK cells, while autologous MSCs were lysed by NK cells only. NK cell-mediated lysis was inversely correlated with the expression of HLA class I on MSCs. Lysis of autologous MSCs was not dependent on culturing of MSCs in FBS, and MSCs in suspension as well as adherent to plastic were lysed by NK cells. Pretransplant recipient PBMCs did not lyse donor MSCs, but PBMCs isolated 3, 6, and 12 months after transplantation showed increasing lysing ability. After 12 months, CD8(+) T-cell-mediated lysis of donor MSCs persisted, indicating there was no evidence for desensitization against donor MSCs. Lysis of MSCs is important to take into account when MSCs are considered for clinical application. Our results suggest that the HLA background of MSCs and timing of MSC administration are important for the efficacy of MSC therapy.
- Published
- 2011
- Full Text
- View/download PDF
31. Deficient TNF-alpha and IFN-gamma production correlates with nondetectable donor-specific cytotoxicity after clinical kidney transplantation.
- Author
-
van Besouw NM, de Kuiper R, van der Mast BJ, van de Wetering J, Baan CC, and Weimar W
- Subjects
- Adrenal Cortex Hormones therapeutic use, Cytotoxicity, Immunologic, Drug Therapy, Combination, Family, HLA Antigens analysis, Humans, Immunosuppressive Agents therapeutic use, Interleukin-10 blood, Interleukin-4 blood, Interleukin-6 blood, Isoantigens immunology, Kidney Transplantation immunology, Kidney Transplantation pathology, Living Donors, Monocytes cytology, Monocytes physiology, Prospective Studies, T-Lymphocytes immunology, Tumor Necrosis Factor-alpha blood, fas Receptor, Interferon-gamma immunology, Kidney Transplantation physiology, T-Lymphocytes, Cytotoxic immunology, Tumor Necrosis Factor-alpha immunology
- Abstract
Background: We previously reported that no cytotoxic T-lymphocyte precursor frequencies (CTLpf) were found in 60% of patients on azathioprine or mycophenolate mofetil+Pred long after kidney transplantation. We questioned whether the absence of donor-specific CTLpf was associated with low levels of stimulatory Th1 (tumor necrosis factor [TNF]-alpha, interferon [IFN]-gamma) or high levels of regulatory Th2 (interleukin [IL]-4, IL-6, IL-10) cytokines., Methods: In this study, peripheral blood monocyte cells (PBMC) were stimulated with irradiated donor cells. After 7 days, cytokine production was determined by cytokine bead array, and CTLpf by limiting dilution assay., Results: Patients with detectable CTLpf (> or =10/10(6) PBMC) had significantly higher levels of TNF-alpha (P=0.04) and IFN-gamma (P=0.02) than patients with nondetectable CTLpf (<10/10(6) PBMC). Donor-reactive IL-4, IL-6, and IL-10 production was comparable in both patient groups. Additionally, CTLpf was positively correlated with TNF-alpha (rs=0.54, P=0.0003) and IFN-gamma (rs=0.64, P<0.0001) production., Conclusion: The absence of donor-specific CTLp after transplantation correlates with low levels of stimulatory cytokines, not with elevated levels of regulatory cytokines.
- Published
- 2009
- Full Text
- View/download PDF
32. After discontinuation of calcineurin inhibitors, tapering of mycophenolate mofetil further impairs donor-directed cytotoxicity.
- Author
-
van Besouw NM, van de Wetering J, van der Mast BJ, de Kuiper R, Baan CC, and Weimar W
- Subjects
- Azathioprine administration & dosage, Azathioprine immunology, Calcineurin immunology, Cohort Studies, Dose-Response Relationship, Drug, Graft vs Host Reaction immunology, Humans, Leukocytes, Mononuclear, Lymphocyte Culture Test, Mixed, Mycophenolic Acid administration & dosage, Mycophenolic Acid analogs & derivatives, Prednisone administration & dosage, Prednisone immunology, T-Lymphocytes, Cytotoxic immunology, Calcineurin Inhibitors, Graft vs Host Reaction drug effects, Immunosuppressive Agents administration & dosage, Immunosuppressive Agents immunology, Kidney Transplantation immunology, T-Lymphocytes, Cytotoxic drug effects
- Abstract
Background: Recently, we described a significant decrease in donor-specific cytotoxic T-lymphocyte precursor frequency (CTLpf) after discontinuation of calcineurin inhibitors (CNI), while the proliferative capacity in mixed lymphocyte culture (MLC), and the number of interferon-gamma (IFN-gamma) producing cells (pc) in Elispot remained unchanged., Methods: We tested T-cell reactivity in CNI free patients with stable renal graft function, on mycophenolate mofetil (MMF) or azathioprine (AZA) plus prednisone, who were tapered to 50% of their MMF or AZA dose., Results: Furthermore, tapering of the MMF or AZA dose resulted in a decrease of donor-reactive CTLpf in all patients with detectable CTLpf. Detectable numbers decreased from a median of 32 to 8 CTLp/10(6) peripheral blood mononuclear cell (PBMC). No effect on third-party reactive CTLpf was found, while the T-cell reactivity to donor and third-party cells as tested in MLC and in IFN-gamma Elispot was not affected either by tapering of immunosuppression. Third-party reactivity was significantly higher than donor-specific reactivity in all tests. A control group showed no changes in any of the in vitro assays., Conclusion: Both withdrawal of CNI and tapering of MMF or AZA dose decreases the donor-specific CTLpf. Our data suggest that reduction of immunosuppression results in a specific decrease of donor-directed cytotoxic capacity of immunocompetent cells, while their proliferation and cytokine production capacity remained unchanged. Immunosuppression hinders development of cytotoxic non-responsiveness.
- Published
- 2008
- Full Text
- View/download PDF
33. Poor expression of T cell-derived cytokines and activation and proliferation markers in early rheumatoid synovial tissue.
- Author
-
Smeets TJ, Dolhain RJEM, Miltenburg AM, de Kuiper R, Breedveld FC, and Tak PP
- Subjects
- Adult, Aged, Aged, 80 and over, Arthritis, Rheumatoid etiology, Arthritis, Rheumatoid pathology, Cell Division, Female, Humans, Immunohistochemistry, Interferon-gamma metabolism, Ki-67 Antigen metabolism, Lymphocyte Activation, Male, Middle Aged, Receptors, Interleukin-2 metabolism, Synovial Membrane pathology, T-Lymphocytes pathology, Time Factors, Arthritis, Rheumatoid immunology, Cytokines metabolism, Synovial Membrane immunology, T-Lymphocytes immunology
- Abstract
We compared the state of activation and proliferation of T cells in synovial tissue (ST) from rheumatoid arthritis (RA) patients in early and late stages of the disease to find out whether T-cell-driven immune responses vary during the course of the disease. ST was obtained from 12 patients with early RA (< 1 year) and 12 patients with longstanding RA (> 5 years). T cells and interferon-gamma (IFN-gamma)-positive cells were detected in ST using immunohistologic methods. To determine the percentage of T cells expressing the interleukin-2 receptor, IFN-gamma, or the proliferation associated antigen Ki-67, immunofluorescence double-staining techniques were used. The scores for the number of T cells and for the expression of IFN-gamma as well as the percentages of T cells expressing CD25, IFN-gamma, or Ki-67 in rheumatoid synovium were not dependent on disease duration. These results do not support the assumption that the responsiveness of T cells in ST of RA patients differs between early and late stages of the disease. The data indicate that at present no arguments exist that the effect of T-cell-directed interventions on synovial inflammation might vary in different stages of the disease., (Copyright 1998 Academic Press.)
- Published
- 1998
- Full Text
- View/download PDF
34. Interleukin-6 activity in paired samples of synovial fluid. Correlation of synovial fluid interleukin-6 levels with clinical and laboratory parameters of inflammation.
- Author
-
Miltenburg AM, van Laar JM, de Kuiper R, Daha MR, and Breedveld FC
- Subjects
- Adult, Aged, Humans, Immunoglobulin G analysis, Immunoglobulin M analysis, Leukocyte Count, Middle Aged, Arthritis, Rheumatoid immunology, Interleukin-6 analysis, Synovial Fluid chemistry
- Abstract
Paired synovial fluid (SF) samples obtained from the knees of 12 arthritis patients were studied to establish a relation between parameters of local inflammatory activity and SF interleukin-6 (IL-6) levels. Local disease activity was scored using joint temperature, swelling and pain as clinical parameters of inflammation. SF samples were assayed for laboratory parameters of inflammation such as leucocyte content, the percentage polymorphonuclear cells, the pH, and for immunoglobulin levels (IgG, IgM). SF IL-6 concentrations were determined using the B9-bioassay. Within individual patients the local activity of inflammation as measured using clinical parameters was found to be related to the local SF IL-6 level. When considering the total group of patients, a correlation (P less than 0.001) was found between the clinical parameters of local inflammation and the SF IL-6 levels. Furthermore, IL-6 levels were found to correlate with leucocyte counts (P less than 0.02), the percentage of polymorphonuclear cells (P less than 0.10), the pH value (P less than 0.01), but not with SF IgM and IgG concentrations.
- Published
- 1991
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.